Inclusion Criteria:

• Inoperable patients
• histologically confirmed HCC or patients who refuse surgery and who otherwise (e.g. due to the advanced tumor stage) are not applicable for palliative local therapy (e.g. PEI, TACE, RFTA).
• Age: 18 years or older

Exclusion Criteria:

General:

• Patient with symptomatic Cholecyst-/Choledocholithiasis
• Patient with severe psychiatric disease.
• Participation in another clinical trial within the last 4 weeks.
• Simultaneous participation in another clinical examination.
• Legally incapacitated patient, who is not able, to understand nature, meaning and consequence of the study.
• Continuous drug or alcohol abuse.
• Patient with known HIV infection and antiretroviral therapy.
• Patient with not controllable infection disease.
• Pregnancy.

Study- and indication-specific exclusion criteria:

• Secondary malignant tumor without complete remission.
• Secondary malignant tumor with complete remission but current adjuvant therapy.
• Preliminary or current therapy with tamoxifen
• Pretreatment of the HCC.
• First-time diagnosis > 6 months before inclusion into the study.
• Severe hepatic encephalopathy, refractory to any treatment.
• Patients with operable HCC.
• Contraindication to i.m. injections.
• Hypersensitivity to octreotide.